Quadramet
Samarium-153-ethylene diamine tetramethylene phosphonate, Samarium-153 EDTMP, Quadramet, or simply Samarium-153 is a complex of a radioisotope of the lanthanide element Samarium with carrier EDTMP which is used to treat pain when cancer has spread to the bone. Samarium-153 is injected into a vein and distributes throughout the body. Samarium-153 EDTMP homes in on areas where cancer has invaded the bone. Once there, the radioisotope emits beta particles (electrons) which kill the nearby cancer cells. Pain begins to improve in the first week for most people and the effects can last several months. It is commonly used in lung cancer, prostate cancer, breast cancer, and osteosarcoma. Side effects result from radiation to the bone marrow and include thrombocytopenia and leukopenia.
Source: Wikipedia, Quadramet, http://en.wikipedia.org/wiki/Quadramet (as of August 8, 2008).
Related Articles:
- Early Use Of Radiation Therapy Associated With Shorter Survival In Multiple Myeloma
- Stem Cell Transplantation May Be Underutilized In Multiple Myeloma Patients In Their 80s
- Darzalex May Affect Different Uninvolved Immunoglobulins Differently
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Common Measures Of Heart And Blood Vessel Health May Predict Risk Of Heart-Related Side Effects During Treatment With Kyprolis
